RU2520212C2 - 2-арилпропионовые кислоты и производные, и фармацевтические композиции, содержащие указанные соединения - Google Patents

2-арилпропионовые кислоты и производные, и фармацевтические композиции, содержащие указанные соединения Download PDF

Info

Publication number
RU2520212C2
RU2520212C2 RU2011114992/04A RU2011114992A RU2520212C2 RU 2520212 C2 RU2520212 C2 RU 2520212C2 RU 2011114992/04 A RU2011114992/04 A RU 2011114992/04A RU 2011114992 A RU2011114992 A RU 2011114992A RU 2520212 C2 RU2520212 C2 RU 2520212C2
Authority
RU
Russia
Prior art keywords
amino
phenyl
trifluoromethyl
thiazol
methyl
Prior art date
Application number
RU2011114992/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2011114992A (ru
Inventor
Марчелло Аллегретти
Андреа АРАМИНИ
Джанлука Бьянкини
Мария Кандида ЧЕСТА
Original Assignee
Домпе С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Домпе С.П.А. filed Critical Домпе С.П.А.
Publication of RU2011114992A publication Critical patent/RU2011114992A/ru
Application granted granted Critical
Publication of RU2520212C2 publication Critical patent/RU2520212C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2011114992/04A 2008-09-18 2009-09-18 2-арилпропионовые кислоты и производные, и фармацевтические композиции, содержащие указанные соединения RU2520212C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08164605A EP2166006A1 (en) 2008-09-18 2008-09-18 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
EP08164605.1 2008-09-18
PCT/EP2009/062109 WO2010031835A2 (en) 2008-09-18 2009-09-18 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
RU2011114992A RU2011114992A (ru) 2012-10-27
RU2520212C2 true RU2520212C2 (ru) 2014-06-20

Family

ID=40291117

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011114992/04A RU2520212C2 (ru) 2008-09-18 2009-09-18 2-арилпропионовые кислоты и производные, и фармацевтические композиции, содержащие указанные соединения

Country Status (17)

Country Link
US (1) US8624036B2 (enExample)
EP (2) EP2166006A1 (enExample)
JP (1) JP5571669B2 (enExample)
CN (1) CN102159558B (enExample)
AU (1) AU2009294558B2 (enExample)
CA (1) CA2737099C (enExample)
CY (1) CY1116176T1 (enExample)
DK (1) DK2346841T3 (enExample)
ES (1) ES2534634T3 (enExample)
HR (1) HRP20150395T1 (enExample)
IL (1) IL211683A (enExample)
PL (1) PL2346841T3 (enExample)
PT (1) PT2346841E (enExample)
RU (1) RU2520212C2 (enExample)
SI (1) SI2346841T1 (enExample)
SM (1) SMT201500098B (enExample)
WO (1) WO2010031835A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2706232C2 (ru) * 2015-01-15 2019-11-15 Идорсиа Фармасьютиклз Лтд Производные (r)-2-метил-пиперазина в качестве модуляторов cxcr3 рецептора
RU2781280C2 (ru) * 2017-05-30 2022-10-11 Домпе' Фармачеутичи С.П.А. Ингибиторы il-8 для применения в лечении и/или профилактике вторичных бактериальных инфекций

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2634185T3 (en) 2012-03-02 2016-03-21 Sareum Ltd Tyk2 kinase inhibitors
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
CA2941824C (en) * 2013-09-03 2020-08-25 Sareum Limited Substituted phenylamino-oxazole-4-carboxylic acid amides as tyk2 kinase inhibitors
EP3117835A1 (en) * 2015-07-14 2017-01-18 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment of certain urological disorders
RS62427B1 (sr) 2016-01-15 2021-11-30 Dompe Farm Spa Il-8 inhibitori za primenu u lečenju periferne neuropatije izazvane hemoterapijom
EP3192504A1 (en) 2016-01-15 2017-07-19 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
US11291641B2 (en) 2016-10-03 2022-04-05 The Children's Medical Center Corporation Prevention and treatment of diabetic nephropathy
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
EP3342407A1 (en) * 2017-01-03 2018-07-04 Dompé farmaceutici S.p.A. Il-8 inihibitors for use in the treatment of some urological disorders
EP3409277A1 (en) * 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections
EP3476390A1 (en) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
EP3868369A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
EP3868368A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof
EP4008325A1 (en) 2020-12-02 2022-06-08 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
CN115397404A (zh) 2020-03-26 2022-11-25 东佩制药股份公司 用于治疗covid-19的cxcl8抑制剂
EP3884932A1 (en) 2020-03-26 2021-09-29 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
EP3907214A1 (en) * 2020-05-04 2021-11-10 Dompe' Farmaceutici S.P.A. Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use
KR20230110751A (ko) * 2020-11-05 2023-07-25 이칸 스쿨 오브 메디슨 엣 마운트 시나이 골수섬유증의 치료에 사용하기 위한 cxcr1/cxcr2 억제제
EP4052702A1 (en) 2021-03-04 2022-09-07 Dompé farmaceutici S.p.a. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures
EP4397305A1 (en) 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid
EP4406942A1 (en) * 2023-01-26 2024-07-31 Dompe' Farmaceutici S.P.A. Stable monohydrate of df2755a and process for its preparation
EP4563594A1 (en) 2023-11-28 2025-06-04 Dompe' Farmaceutici SpA Cxcl8 inhibitors for use in the treatment of tumors with low stromal cav1 levels

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025528A (en) * 1973-10-24 1977-05-24 Shionogi & Co., Ltd. Thiazole derivatives of benzoic and phenylalkanoic acids
GB1481465A (en) * 1973-10-24 1977-07-27 Shionogi & Co Thiazole derivatives and the production thereof
SU1554763A3 (ru) * 1985-10-16 1990-03-30 Мицубиси Касей Корпорейшн (Фирма) Способ получени производных тиазола или их солей с щелочными металлами
WO2000024710A1 (en) * 1998-10-23 2000-05-04 Dompe' S.P.A. N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
WO2001058852A2 (en) * 2000-02-11 2001-08-16 Dompé S.p.A. (r)-2-aryl-propionamides, useful in the inhibition of il-8-induced chemiotaxis of neutrophils
WO2003043625A1 (en) * 2001-11-20 2003-05-30 Dompe S.P.A. 2-aryl-propionic acids and pharmaceutical compositions containing them
WO2007060215A2 (en) * 2005-11-24 2007-05-31 Dompe' Pha.R.Ma S.P.A. (r)-arylkylamino derivatives and pharmaceutical compositions containing them

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5537556B2 (enExample) * 1973-12-27 1980-09-29
JPS565747B2 (enExample) * 1973-10-24 1981-02-06
JPS5629871B2 (enExample) * 1974-05-22 1981-07-10
IT1298214B1 (it) 1998-01-28 1999-12-20 Dompe Spa Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche.
WO2003062215A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
ES2333445T3 (es) * 2004-03-23 2010-02-22 Dompe' S.P.A. Derivados del acido 2-fenilpropionico y composiciones farmaceuticas que los contienen.
PL2024329T3 (pl) * 2006-05-18 2014-03-31 Dompe Farm Spa (2r)-2-[(4-sulfonylo)aminofenylo]propanoamidy i zawierające je kompozycje farmaceutyczne
US8440711B2 (en) * 2006-12-19 2013-05-14 Dompe Pha.R.Ma S.P.A. 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them
PL2201006T3 (pl) * 2007-10-18 2011-08-31 Dompe Farm Spa Pochodne (R)-4-(heteroarylo)fenyloetylu i zawierające je kompozycje farmaceutyczne

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025528A (en) * 1973-10-24 1977-05-24 Shionogi & Co., Ltd. Thiazole derivatives of benzoic and phenylalkanoic acids
GB1481465A (en) * 1973-10-24 1977-07-27 Shionogi & Co Thiazole derivatives and the production thereof
SU1554763A3 (ru) * 1985-10-16 1990-03-30 Мицубиси Касей Корпорейшн (Фирма) Способ получени производных тиазола или их солей с щелочными металлами
WO2000024710A1 (en) * 1998-10-23 2000-05-04 Dompe' S.P.A. N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
WO2001058852A2 (en) * 2000-02-11 2001-08-16 Dompé S.p.A. (r)-2-aryl-propionamides, useful in the inhibition of il-8-induced chemiotaxis of neutrophils
WO2003043625A1 (en) * 2001-11-20 2003-05-30 Dompe S.P.A. 2-aryl-propionic acids and pharmaceutical compositions containing them
WO2007060215A2 (en) * 2005-11-24 2007-05-31 Dompe' Pha.R.Ma S.P.A. (r)-arylkylamino derivatives and pharmaceutical compositions containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATANI G.A. et al: "BIOISOSTERISM: A RATIONAL APPROACH IN DRUG DESIGN", CHEMICAL REVIEWS, 1996, vol.96, no.8, p.3147-3176. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2706232C2 (ru) * 2015-01-15 2019-11-15 Идорсиа Фармасьютиклз Лтд Производные (r)-2-метил-пиперазина в качестве модуляторов cxcr3 рецептора
RU2781280C2 (ru) * 2017-05-30 2022-10-11 Домпе' Фармачеутичи С.П.А. Ингибиторы il-8 для применения в лечении и/или профилактике вторичных бактериальных инфекций

Also Published As

Publication number Publication date
WO2010031835A3 (en) 2010-06-24
US8624036B2 (en) 2014-01-07
WO2010031835A2 (en) 2010-03-25
EP2346841B1 (en) 2015-01-14
US20110207785A1 (en) 2011-08-25
EP2166006A1 (en) 2010-03-24
AU2009294558B2 (en) 2014-12-18
RU2011114992A (ru) 2012-10-27
CA2737099A1 (en) 2010-03-25
ES2534634T3 (es) 2015-04-27
DK2346841T3 (en) 2015-04-20
IL211683A0 (en) 2011-06-30
PL2346841T3 (pl) 2015-07-31
EP2346841A2 (en) 2011-07-27
AU2009294558A1 (en) 2010-03-25
SMT201500098B (it) 2015-07-09
IL211683A (en) 2014-01-30
JP5571669B2 (ja) 2014-08-13
CA2737099C (en) 2016-07-05
CN102159558B (zh) 2015-01-07
CN102159558A (zh) 2011-08-17
JP2012502957A (ja) 2012-02-02
CY1116176T1 (el) 2017-02-08
BRPI0918759A2 (pt) 2015-12-29
HRP20150395T1 (hr) 2015-06-19
SI2346841T1 (sl) 2015-07-31
PT2346841E (pt) 2015-05-07

Similar Documents

Publication Publication Date Title
RU2520212C2 (ru) 2-арилпропионовые кислоты и производные, и фармацевтические композиции, содержащие указанные соединения
RU2375347C2 (ru) Производные 2-фенилпропионовой кислоты и содержащие их фармацевтические композиции
JP4937479B2 (ja) 好中球のｉｌ−８誘発走化性の阻害に有用なアミド
JP4267922B2 (ja) 多形核細胞及び単核細胞の走化性の阻害剤としてのｒ−２−アリール−プロピオン酸のオメガ−アミノアルキルアミド
JP2005504121A (ja) Ｒ−２−アリール−プロピオン酸のオメガ−アミノアルキルアミドの４級アンモニウム塩及びそれらを含有する医薬組成物
EP1455773B1 (en) 2-aryl-propionic acids and pharmaceutical compositions containing them
EP1606248B1 (en) Sulfonic acids, their derivatives and pharmaceutical compositions containing them
US7652169B2 (en) (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them
JP5208411B2 (ja) ２−アリール−酢酸、その誘導体、及びそれらを含有する医薬組成物
WO2008075184A2 (en) 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them
JP4795242B2 (ja) アミジン及びその誘導体並びにそれを含有する医薬組成物
JP2008528546A (ja) ２−アリールプロピオン酸誘導体の代謝産物及びそれを含有する医薬組成物

Legal Events

Date Code Title Description
PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20151027